Axsome Therapeutics Stock News

Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 7) • Acceleron Pharma Inc (...

Shares of Axsome Therapeutics (NASDAQ: AXSM), a clinical-stage biopharmaceutical company, rocketed 61.5% in April, according to data from S&P; Global Market Intelligence. March was a rough month for

Remdesivir, the investigational Gilead Sciences antiviral drug, looks more likely than ever to become the first treatment authorized by the FDA to treat

Axsome Therapeutics Inc (NASDAQ:AXSM) – SunTrust Banks lifted their FY2021 earnings estimates for Axsome Therapeutics in a report issued on Monday, April 27th. SunTrust Banks analyst J. Lee now fore

Key details in an antidepressant's clinical trial may signal a revolutionary therapy for patients.

Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will repor

Axsome Therapeutics (NASDAQ:AXSM) had its target price increased by SunTrust Banks from $145.00 to $200.00 in a research report sent to investors on Monday morning, The Fly reports. They currently hav

Axsome Therapeutics Inc (NASDAQ:AXSM)’s stock price was up 4% during trading on Tuesday after Guggenheim raised their price target on the stock from $158.00 to $200.00. Guggenheim currently has a bu

Clinical trial of AX-05 showed drug reduces patient agitation Continue reading...

Axsome Shares Jump 25% on Alzheimer’s Study Results, Stocks: AXSM,LLY,RHHBY,ACIU,MOR,ESALY,BIIB, release date:Apr 27, 2020

Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including American Tower, Ferrari and Walt Disney, on Tuesday. HIGHLIGHTS * Amer

Axsome Therapeutics price target raised to $200 from $145 at SunTrust SunTrust AXSM

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Axsome Therapeutics (AXSM) and Alphatec Holdings (ATEC)

Stocks Analysis by Harry Boxer covering: Alphabet Inc Class A, Bed Bath & Beyond Inc, Crude Oil WTI Futures, AudioCodes Ltd. Read Harry Boxer's latest article on Investing.com